Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Leukemia, Myeloid, Acute 2Leukemia 2Urinary Bladder Neoplasms 1Recurrence 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 27Cetuximab 17Radiotherapy 14Carboplatin 14pembrolizumab 11Paclitaxel 11Drug Therapy 8Radiotherapy, Intensity-Modulated 7Nivolumab 7Fluorouracil 7Erlotinib Hydrochloride 7Radiation 6Docetaxel 5130-nm albumin-bound paclitaxel 5Panitumumab 4Chemoradiotherapy 3Capecitabine 3Bevacizumab 3Albumin-Bound Paclitaxel 3Afatinib 3selinexor 2figitumumab 2Restraint, Physical 2Radiosurgery 2Methotrexate 2Lapatinib 2Everolimus 2Esophagectomy 2Cyclophosphamide 2zalutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Squamous Cell × lirilumab × Clear all
NCT03341936 2025-06-18

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
29 enrolled 11 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡